Trial Profile
Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary) ; Clopidogrel
- Indications Attention-deficit hyperactivity disorder; Depressive disorders; Thrombosis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 04 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 27 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.